Epizyme, Inc.

Eisai R&d Management Co., Ltd.

Health Research, Inc.

Heike Keilhack

Sarah Kathleen Knutson

Kevin Wayne Kuntz

Natalie Warholic

Richard Chesworth

Kenneth William Duncan

Masashi Seki

Christine Klaus

Syuji Shirotori

Satoshi Kawano

Timothy James Nelson Wigle

Timothy J N Wigle

Danielle Johnston Blackwell

Yuta Suzuki

Larisa Reyderman

Roberto Pili

Brett Truitt

Tsukasa Murase

Futoshi Shikata

Lone Ottesen

Timothy James Wigle

Danielle L Johnston

L Danielle Johnston

The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Aryl-OR heteroaryl-substituted benzene compounds

Aryl-or heteroaryl-substituted benzene compounds

The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

Method for treating cancer

The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Methods of treating cancer

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

EZH2 inhibitors for treating lymphoma

The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Combination therapy for treating cancer

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.

Growing community of inventors

Belmont, MA, United States of America

Heike Keilhack